drugset / Trial / NCT04804033
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Timeline
- Start
- 2021-03-26
- Primary completion
- 2024-03-21
- Completion
- 2024-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Zavegepant | Small molecule | 100 mg | Oral |
| Comparator | Zavegepant | Small molecule | 200 mg | Oral |